SCHEMBL2352880

SCHEMBL2352880

COc1cc(CCC(=O)O)c(-c2ccc[nH]c2=O)cc1C(C)(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.42
PARP1 P09874 1/20 0.39
HTR2A P28223 1/20 0.37
EGFR P00533 1/20 0.37
PDGFRB P09619 1/20 0.37
FGFR1 P11362 1/20 0.37
KDR P35968 1/20 0.37
S1PR1 P21453 1/20 0.36
POLB P06746 1/20 0.36
NPSR1 Q6W5P4 1/20 0.35
CYP1A1 P04798 1/20 0.35
ELANE P08246 1/20 0.34
FFAR1 O14842 2/20 0.34
NR1H4 Q96RI1 1/20 0.33
TP53 P04637 1/20 0.33
MAPT P10636 1/20 0.33
FFAR4 Q5NUL3 1/20 0.33
PTGER1 P34995 1/20 0.33
PTGER4 P35408 1/20 0.33
PTGER3 P43115 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2362800 0.90 CYP3A4 (0.44) CYP3A4HTR2APDGFRBPOLBCYP1A1
SCHEMBL2354510 0.89 CYP3A4 (0.41) CYP3A4HTR2ANPSR1CYP1A1NR1H4
SCHEMBL2362428 0.88 CYP3A4 (0.44) CYP3A4HTR2APOLBCYP1A1TP53
SCHEMBL2362488 0.85 HTR2A (0.54) CYP3A4HTR2ACYP1A1
SCHEMBL2363467 0.85 CYP3A4 (0.43) CYP3A4HTR2APOLBCYP1A1NR1H4
SCHEMBL2364691 0.83 ICMT (0.44) CYP3A4HTR2ACYP1A1TP53
SCHEMBL3308904 0.83 CYP3A4 (0.42) CYP3A4HTR2ACYP1A1TP53
SCHEMBL2363082 0.83 HTR2A (0.44) CYP3A4HTR2ACYP1A1TP53
SCHEMBL3308176 0.82 CYP3A4 (0.42) CYP3A4POLBCYP1A1NR1H4TP53
SCHEMBL2364475 0.82 CYP3A4 (0.42) CYP3A4HTR2APOLBCYP1A1NR1H4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232271-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-07-31 US claimed
US-20100111900-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS ROCHE PALO ALTO LLC 2010-05-06 US claimed
US-8232271-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-07-31 US disclosed
EP-2350007-A1 HETEROCYCLIC ANTIVIRAL ARYLPYRIDONE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2011-08-03 EP disclosed
US-20100111900-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS ROCHE PALO ALTO LLC 2010-05-06 US disclosed
WO-2010049331-A1 HETEROCYCLIC ANTIVIRAL ARYLPYRIDONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100111900-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS POLR2A, EIF2AK2, POLR2B CYP3A4 423/4885PARP1 482/4885HTR2A 2942/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.